RxDoctor Payments Data

Ayman Latif, DPM

Podiatrist · Middletown, CTNPI 1043488422

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.4% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Stryker at 25.1% of the total. Reporting peaked in 2019 at $954 and has fallen 65.6% since, to $328 in 2025.

$2,796in general payments, 2019–2025

Across 43 payments — averaging $65.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$702
  • Davol Inc.$252
  • Celularity Inc.$234
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$217
  • Treace Medical Concepts, Inc.$159
  • Smith+Nephew$155
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$2,64094%
  • Education$1576%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,796 in reported general payments places this provider in the 80th percentile of 119 podiatrist providers in Connecticut.

See all podiatrist providers in Connecticut

Medicare billing

Part B allowed, 2024
$129,984
Medicare patients
485
Services billed
2,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium35$2,741
CiclopiroxCiclopirox Olamine118$1,644
Ciclopirox55$1,000
Clotrimazole42$832
Ammonium Lactate30$644
Terbinafine Hcl62$466
Methylprednisolone39$305
Silver Sulfadiazine33$179
Doxycycline Hyclate24$138
Cefadroxil17$85
Meloxicam35$78
SsdSilver Sulfadiazine11$67

Paid to pharmacies, not to this prescriber.

Other podiatrist in Middletown

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →